https://www.oxeiabiopharma.com/news daily 0.75 2026-01-26 https://www.oxeiabiopharma.com/news/crowdfunding-for-biotechs monthly 0.5 2026-01-26 https://www.oxeiabiopharma.com/news/iyt99gjpwdtisnv7gjo3sgjpbtaehd monthly 0.5 2026-01-14 https://www.oxeiabiopharma.com/news/wyand-bansal-oxeia-biopharmaceuticals-team-up monthly 0.5 2026-01-11 https://www.oxeiabiopharma.com/news/a-special-call-out-to-mandi-dickey-for-a-great-discussion-on-post-concussion-care monthly 0.5 2025-10-09 https://www.oxeiabiopharma.com/news/oxeia-biopharma-named-most-innovative-mtbi-biopharma-company-2025-by-global-health-pharma monthly 0.5 2025-10-07 https://www.oxeiabiopharma.com/news/nrtimescouk/exploring-the-gap-in-traumatic-brain-injury-and-concussion-treatment-y9eb3 monthly 0.5 2025-06-30 https://www.oxeiabiopharma.com/news/nrtimescouk/exploring-the-gap-in-traumatic-brain-injury-and-concussion-treatment monthly 0.5 2025-06-30 https://www.oxeiabiopharma.com/news/light-within-the-black-hole-of-concussion-therapies monthly 0.5 2025-02-22 https://www.oxeiabiopharma.com/news/nbsciencecafe monthly 0.5 2024-11-18 https://www.oxeiabiopharma.com/news/https/wwwddw-onlinecom/new-podcast-the-unmet-critical-need-for-concussion-drug-therapies-32171-202410 monthly 0.5 2024-11-18 https://www.oxeiabiopharma.com/news/neuroscience-advances-research-opportunities monthly 0.5 2024-10-19 https://www.oxeiabiopharma.com/news/developments-in-concussion-therapies monthly 0.5 2024-10-19 https://www.oxeiabiopharma.com/news/https/results-of-research-at-the-university-of-kansas-medical-center monthly 0.5 2024-10-19 https://www.oxeiabiopharma.com/news/concussion-drug-therapies-on-the-horizon monthly 0.5 2024-10-19 https://www.oxeiabiopharma.com/news/game-on-for-concussion-therapies monthly 0.5 2024-10-19 https://www.oxeiabiopharma.com/news/ku-medical-center-researcher-testing-drug-to-improve-concussion-symptoms monthly 0.5 2024-10-19 https://images.squarespace-cdn.com/content/v1/5f2d495f75ff984d317100d7/aaee9e07-2d56-44d9-83b4-b518e113c571/news-concussion.jpeg Oxeia Biopharma In the News - KU Medical Center researcher testing drug to improve concussion symptoms - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.oxeiabiopharma.com/news/concussion-drug-study-shows-positive-early-results monthly 0.5 2024-10-19 https://www.oxeiabiopharma.com/news/7cpn7nibhncxd32azzwozq63a0q4e3 monthly 0.5 2024-10-19 https://images.squarespace-cdn.com/content/v1/5f2d495f75ff984d317100d7/7c0cef56-087f-48bf-9c19-7e29f0ddc503/OXE103+poster_ACRM+2023.jpg Oxeia Biopharma In the News - ACRM Conference Presentation: The injection of Ghrelin (OXE-103) improves subacute concussion symptom burden and quality of life - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.oxeiabiopharma.com/news/a-tough-puzzle-complexity-slows-drug-development-for-concussions monthly 0.5 2024-10-19 https://www.oxeiabiopharma.com/news/roll-call-brain-injury-awareness-we-need-new-treatment monthly 0.5 2024-10-19 https://www.oxeiabiopharma.com/news/us-veterans-tbi monthly 0.5 2024-10-19 https://www.oxeiabiopharma.com/news/neurologylive/phase2-trial-oxe103-concussion-positive-interim-results monthly 0.5 2024-10-19 https://www.oxeiabiopharma.com/news/oxeia-announces-positive-interim-results monthly 0.5 2024-10-19 https://www.oxeiabiopharma.com/news/concussionmanagement monthly 0.5 2024-10-19 https://images.squarespace-cdn.com/content/v1/5f2d495f75ff984d317100d7/4ddf149a-a6a3-416d-ae8a-5aa09bdc2455/concussion+management.jpg Oxeia Biopharma In the News - KUMC: The University of Kansas Health System Center for Concussion Management will hold its 4th Annual Symposium on August 6, 2022. - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.oxeiabiopharma.com/news/morningmedicalupdate monthly 0.5 2024-10-19 https://www.oxeiabiopharma.com/news/clinical-trial-for-concussion-therapeutic-on-recovery monthly 0.5 2026-01-10 https://www.oxeiabiopharma.com/news/its-time-to-take-the-brain-injury-epidemic-seriously monthly 0.5 2024-10-19 https://www.oxeiabiopharma.com/news/https/wwwoxeiabiopharmacom/news/oxeia-announces-new-board-and-mgt-team-members-hq-move-to-boston monthly 0.5 2024-10-19 https://www.oxeiabiopharma.com/news/oxeia-announces-phase-2-trial-for-oxe103-zht7k monthly 0.5 2024-10-19 https://www.oxeiabiopharma.com/news/roll-call-concussions-and-first-responders-snc8l monthly 0.5 2024-10-19 https://www.oxeiabiopharma.com/news/oxeia-ceo-michael-wyand-participated-in-onenucleus-biowednesday-webinar-prevention-vscure-rnrp6 monthly 0.5 2024-10-19 https://www.oxeiabiopharma.com/news/oxeia-ceo-michael-wyand-participated-in-onenucleus-biowednesday-webinar-prevention-vscure monthly 0.5 2024-10-19 https://www.oxeiabiopharma.com/news/one-nucleus-dr-michael-wyand-to-participate-in-panel monthly 0.5 2024-10-19 https://www.oxeiabiopharma.com/news/roll-call-concussions-and-first-responders monthly 0.5 2024-10-19 https://www.oxeiabiopharma.com/news/covid-didnt-bench-nfl-football-but-head-injuriesconcussions-could monthly 0.5 2024-10-19 https://www.oxeiabiopharma.com/news/drug-discovery-news-one-nucleus-announces-life-science-award-shortlist monthly 0.5 2024-10-19 https://www.oxeiabiopharma.com/news/brainhealthmagazineoxeia monthly 0.5 2024-10-19 https://www.oxeiabiopharma.com/news/gen-spotting-brain-injury-in-the-bloodstream monthly 0.5 2024-10-19 https://www.oxeiabiopharma.com/news/oxeia-announces-initiation-of-phase-2-trial-for-oxe103 monthly 0.5 2024-10-19 https://www.oxeiabiopharma.com/news/concussion-alliance-interview monthly 0.5 2024-10-19 https://www.oxeiabiopharma.com/news/new-treatment-for-concussion-with-dr-bansal-onrecovery-now-with-kim-justus monthly 0.5 2026-01-10 https://www.oxeiabiopharma.com/news/slwfdieoe9anbnz1cry3diy57qq60t monthly 0.5 2024-10-19 https://www.oxeiabiopharma.com/news/y415sy1n11xv4inel2b3zw530mbh73 monthly 0.5 2024-10-19 https://www.oxeiabiopharma.com/news/q10mxz7opxqqa34gpsn4or5nikeu8h monthly 0.5 2024-10-19 https://www.oxeiabiopharma.com/news/kzonez2vmrbtccrkro4v941bft1t14 monthly 0.5 2024-10-19 https://www.oxeiabiopharma.com/news/co7jz100j59gdbk1mm9acttvkz3vjn monthly 0.5 2024-10-19 https://www.oxeiabiopharma.com/news/soul-ecsn4 monthly 0.5 2024-10-19 https://www.oxeiabiopharma.com/news/summer-retreat-x7bgc monthly 0.5 2024-10-19 https://www.oxeiabiopharma.com/news/yoga-mphjz monthly 0.5 2024-10-19 https://www.oxeiabiopharma.com/news/exploring-6yhnj monthly 0.5 2024-10-19 https://www.oxeiabiopharma.com/news/604w88sr7fc8jxropbchz9xepmbsv5 monthly 0.5 2024-10-19 https://www.oxeiabiopharma.com/blog daily 0.75 2026-02-02 https://www.oxeiabiopharma.com/blog/alex-smith-on-golic-amp-golic monthly 0.5 2026-02-02 https://www.oxeiabiopharma.com/blog/alex-smith-on-espns-the-john-keim-report-heres-a-company-actually-trying-to-do-something monthly 0.5 2026-02-02 https://www.oxeiabiopharma.com/blog/alex-smith-on-the-dan-patrick-show-there-are-no-approved-treatments-for-concussions monthly 0.5 2026-02-02 https://www.oxeiabiopharma.com/blog/dr-wyand-and-dr-vishal-bansal-on-recovery-now-why-concussion-treatment-needs-to-evolve monthly 0.5 2026-02-02 https://www.oxeiabiopharma.com/blog/can-any-good-come-from-the-nyc-nfl-shootings monthly 0.5 2025-08-03 https://www.oxeiabiopharma.com/blog/nfl-heroes-are-proof-we-need-to-do-more-about-brain-injuries-fb94z monthly 0.5 2025-03-03 https://www.oxeiabiopharma.com/blog/nfl-heroes-are-proof-we-need-to-do-more-about-brain-injuries monthly 0.5 2024-11-27 https://www.oxeiabiopharma.com/blog/the-pentagon-knows-it-has-a-problem-with-veterans-with-tbinbsp-new-data-shows-its-extent monthly 0.5 2023-10-02 https://www.oxeiabiopharma.com/blog/one-million-americans-go-to-emergency-rooms-after-falls-each-yearkeep-that-in-mind-on-september-22nd-and-everyday monthly 0.5 2023-09-21 https://www.oxeiabiopharma.com/blog/we-need-more-than-awareness-of-concussions-we-need-a-cure monthly 0.5 2023-09-15 https://www.oxeiabiopharma.com/blog/convenient-eco-friendly-and-cost-effective-micromobility-alternatives-to-gasoline-powered-cars-resulting-in-more-head-injuries monthly 0.5 2023-08-28 https://www.oxeiabiopharma.com/blog/preventing-workplace-concussions-good-for-employees-and-employers monthly 0.5 2023-08-07 https://www.oxeiabiopharma.com/blog/watch-for-concussions-in-water-sports monthly 0.5 2023-07-31 https://www.oxeiabiopharma.com/blog/study-shows-that-cumulative-force-of-head-impacts-are-the-best-predictors-of-cte monthly 0.5 2023-07-25 https://www.oxeiabiopharma.com/blog/the-high-incidence-of-concussions-among-seniors-is-reason-for-concernbut-new-treatments-may-be-on-the-way monthly 0.5 2023-07-07 https://www.oxeiabiopharma.com/blog/preventing-fatal-and-serious-injuries-caused-by-distracted-driving monthly 0.5 2023-06-21 https://www.oxeiabiopharma.com/blog/https/wwwoxeiabiopharmacom/protecting-youth-athletes-from-concussion monthly 0.5 2023-04-26 https://www.oxeiabiopharma.com/blog/https/wwwoxeiabiopharmacom/school-spring-sports-and-concussions monthly 0.5 2023-04-03 https://www.oxeiabiopharma.com/blog/https/wwwoxeiabiopharmacom/concussions-more-than-just-a-bump-on-the-head monthly 0.5 2023-03-28 https://www.oxeiabiopharma.com/blog/https/wwwoxeiabiopharmacom/march-madness-concussion-risk-in-basketball monthly 0.5 2023-03-20 https://www.oxeiabiopharma.com/blog/https/wwwoxeiabiopharmacom/senator-mitch-mcconnells-concussion-strong-reminder-more-treatment monthly 0.5 2023-03-14 https://www.oxeiabiopharma.com/blog/https/wwwoxeiabiopharmacom/lets-not-fail-our-veterans-its-time-to-find-a-cure-for-concussions monthly 0.5 2022-12-20 https://www.oxeiabiopharma.com/blog/https/wwwoxeiabiopharmacom/tua-tagovailoa-find-concussion-cure monthly 0.5 2022-11-01 https://www.oxeiabiopharma.com/blog/https/wwwoxeiabiopharmacom/distracted-driving monthly 0.5 2022-10-06 https://www.oxeiabiopharma.com/blog/https/wwwoxeiabiopharmacom/concussion-tied-to-poor-youth-academic-outcomes monthly 0.5 2022-09-26 https://www.oxeiabiopharma.com/blog/https/wwwoxeiabiopharmacom/keepingsummerfunandsafe monthly 0.5 2022-06-29 https://www.oxeiabiopharma.com/blog/https/wwwoxeiabiopharmacom/actionstoprotectcombatathletes monthly 0.5 2022-06-24 https://www.oxeiabiopharma.com/blog/https/wwwoxeiabiopharmacom/news/silent-epidemic-invisibleinjuries monthly 0.5 2022-05-25 https://www.oxeiabiopharma.com/blog/moreabouttheunmetneedforconcussiontreatment monthly 0.5 2022-03-01 https://www.oxeiabiopharma.com/blog/oxeiaandthepeoplebehindthecompany monthly 0.5 2022-02-24 https://www.oxeiabiopharma.com/blog/https/wwwoxeiabiopharmacom/news/mountains-were-moved-to-develop-covid19-vaccines monthly 0.5 2022-02-03 https://www.oxeiabiopharma.com/blog/whatisaconcussion-video-ysngk-tfpk8-rexhs monthly 0.5 2025-03-03 https://www.oxeiabiopharma.com/blog/whatisaconcussion-video-ysngk-tfpk8 monthly 0.5 2025-02-25 https://www.oxeiabiopharma.com/blog/whatisaconcussion-video-ysngk monthly 0.5 2025-02-25 https://www.oxeiabiopharma.com/blog/a-friend-and-advocate-for-brain-health-oxeia-supports-richard-sherman-and-other-athletes-making-their-mental-health-a-top-priority monthly 0.5 2021-09-02 https://www.oxeiabiopharma.com/blog/whatisaconcussion-video monthly 0.5 2025-03-03 https://www.oxeiabiopharma.com/blog/oxe-103blog1 monthly 0.5 2021-07-01 https://www.oxeiabiopharma.com/about/about-us daily 0.75 2025-12-27 https://images.squarespace-cdn.com/content/v1/5f2d495f75ff984d317100d7/1600794159809-9IHFORUZFRKB1Z8Y4786/DSC_4229.JPG About https://www.oxeiabiopharma.com/what-we-do/overview daily 0.75 2025-12-27 https://images.squarespace-cdn.com/content/v1/5f2d495f75ff984d317100d7/1600802910371-XYG4EGFN8J26R41PVXOY/DSC_4975.JPG What We Do https://images.squarespace-cdn.com/content/v1/5f2d495f75ff984d317100d7/7c0cef56-087f-48bf-9c19-7e29f0ddc503/OXE103+poster_ACRM+2023.jpg What We Do - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5f2d495f75ff984d317100d7/1600893685263-YOKPINVTREU4UZSCFR46/20-09-03+Photo+3+IMG_7394+Credit+David+Silverman+Photography.JPG What We Do https://images.squarespace-cdn.com/content/v1/5f2d495f75ff984d317100d7/1600893738700-MSJ388F3J4GZCQNBUVO0/Tara+Restivo.jpg What We Do https://images.squarespace-cdn.com/content/v1/5f2d495f75ff984d317100d7/1600893798741-CNOSYJ1YOMN8NAGVB5TA/RichardSherman_1024sq.jpg What We Do https://www.oxeiabiopharma.com/about/leadership daily 0.75 2026-02-20 https://images.squarespace-cdn.com/content/v1/5f2d495f75ff984d317100d7/1600886594941-EV6XCRV2UT58VZ4FALKU/Wyand.jpg Leadership Team - Michael Wyand, DVM, PhD Chief Executive Officer and Director Tobias Keene, D.D.S. Hailing from Richmond, Virginia, Dr. Tobias Keene brings a bit of unabashed Southern hospitality to all his patients. He moved to Washington, D.C. over thirty years ago as a freshman at Ivy College. Right after graduation, he attended World University’s School of Dentistry. Before opening Keene Dental in 1994, he worked for free clinics and some of the finest practices in the District. He is part of the 123 Dental Association and stays up-to-date on the latest dental discoveries. When not striving to keep his patients happy and healthy, he’s enjoys hiking with his family in Rock Creek Park. https://images.squarespace-cdn.com/content/v1/5f2d495f75ff984d317100d7/1600884904612-45REEK32SII82TGPVIP8/Vishal%2BBansal.jpg Leadership Team - Vishal Bansal, MD, FACS Chief Scientific Officer and Co-founder Vishal Bansal, M.D. F.A.C.S. is the Chief Scientific Officer and Co-Founder of Oxeia Biopharmaceuticals. Since 2015, Dr. Bansal is a Director of Trauma Surgery at Scripps Mercy Hospital in San Diego. From 2007 until 2015, Dr. Bansal was on faculty at the University California San Diego as an Associate Professor of Surgery. Dr. Bansal is a clinically active trauma and general surgeon as well as a funded surgical scientist focusing on the physiologic response to brain injury. He has been a principal investigator of three trials in traumatic brain injury. He has nearly 100 peer review publications, book chapters and invited reviews, sits on three national trauma committees, and is a referee for over 25 national and international scientific journals. Dr. Bansal received his undergraduate degree in music from Kalamazoo College and his medical degree from Wayne State University where he graduated Alpha Omega Alpha with high honors. He completed his general surgery internship and residency at The University of Pittsburgh and his fellowship in surgical critical care at University of California San Diego. https://images.squarespace-cdn.com/content/v1/5f2d495f75ff984d317100d7/1600884783607-QTJ4WVBDEWOP8WSEFSON/Kartik+Shah.jpg Leadership Team - Kartik Shah Director and Co-founder Kartik Shah is a member of the Board of Directors and Co-founder of Oxeia Biopharmaceuticals, Inc. He served as the company's Chief Business Officer and Chief Financial Officer until 2019. Mr. Shah identified the lead asset and has led Oxeia's strategy, licensing, planning and intellectual property activities since inception. Prior to founding Oxeia, Mr. Shah was VP of Business Development at Cynvenio Biosystems, a molecular diagnostics startup, where he was responsible for developing research partnerships with big pharma and major cancer centers. Prior to Cynvenio, Mr. Shah was a Director and General Manager at Wireless Generation, a SaaS product and consulting business in K-12 education. His clients included the US Department of Education, New York City Public Schools and the Bill and Melinda Gates Foundation. Earlier in his career, Mr. Shah was a Manager in the Strategy and Corporate Development team at Amgen and a consultant with Oliver, Wyman and Company. He also served as the Chairman of the Board of Trustees for GlobalXFunds from 2008-2018, overseeing 40+ publicly traded ETFs with $10 BN under management. Mr. Shah holds a BSE in Bioengineering and an MS in Biotechnology from the University of Pennsylvania, and an MBA from Harvard Business School. https://images.squarespace-cdn.com/content/v1/5f2d495f75ff984d317100d7/bd7d6d6c-2113-47ac-8322-7fc1e5f89fc2/Amit+Munshi+Headshot.jpg Leadership Team - Amit Munshi Co-founder Amit Munshi is an experienced pharmaceutical executive and Co-founder of Oxeia Biopharmaceuticals, Inc. Mr. Munshi is the Chief Executive Officer of ReNAgade Therapeutics, Inc. Mr. Munshi was most recently President and CEO of Arena Pharmaceuticals Inc. (Nasdaq:ARNA) where he built the company from a $300M market cap into a late clinical-stage company with 37 programs, 4 drugs, and 11 indications before their $6.7B acquisition by Pfizer. Prior to Arena, Mr. Munshi served as President and Chief Executive Officer and a director of Epirus Biopharmaceuticals, Inc. from May 2012 to May 2016. Prior to Epirus, Mr. Munshi served as Chief Executive Officer of Percivia LLC, a biotechnology company, from 2011 to 2012, was a co-founder and served as Chief Business Officer of Kythera Biopharmaceuticals, Inc., from 2005 to 2010, and held multiple leadership positions at Amgen Inc. from 1997 to 2005, including General Manager, Nephrology Europe. Mr. Munshi holds a B.S. in Economics and a B.A. in History from the University of California, Riverside, and an M.B.A. from the Peter F. Drucker Graduate School of Management at Claremont Graduate University. Mr. Munshi has more than 25 years of global biopharmaceutical industry experience in executive management, business development, product development and portfolio management. Mr. Munshi also serves on the board of Cytrellis Biosystems, Inc., a privately held company. https://images.squarespace-cdn.com/content/v1/5f2d495f75ff984d317100d7/12ad9f92-d6f3-4468-b5cd-27f1863c0cba/Ted+Raad+Headshot.jpeg Leadership Team - Ted Raad Director Ted Raad joined Oxeia Biopharmaceuticals Board of Directors in 2021. He has extensive experience building and leading great organizations in both specialty healthcare service and pharmaceutical companies. Mr. Raad is the CEO and Board Director at Pulmatrix, a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology. Prior to his appointment as CEO, he served as PULMATRiX’s Chief Business Officer and led commercial and business development efforts. He has 20 years of commercial healthcare and life science leadership experience and most recently served as Chief Commercial Officer at Option Care, where he helped separate the specialty home infusion business unit from Walgreens to create the nation’s largest independent home infusion provider. Prior to that, he was a business unit head at Sunovion with overall responsibility for CNS and respiratory products, including assets in asthma and COPD. During his time at Sunovion, Mr. Raad led multiple products through clinical development to commercialization and implemented new strategic alliances in the US and Japan. Earlier in his career, he also gained direct launch experience with Sporanox®, Janssen’s oral itraconazole product to treat fungal infections, and brings that experience to the PULMATRiX PUR1900 program. Mr. Raad holds a BS in Business Administration from University of Colorado at Boulder and an MBA from Thunderbird Global School of Global Management. https://images.squarespace-cdn.com/content/v1/5f2d495f75ff984d317100d7/ffc3289f-ef33-4b54-99ca-b3fc1c56f882/Alex+Smith+headshotcropped.jpg Leadership Team - Alex Smith Director Alex Smith joined the Board of Directors of Oxeia Biopharmaceuticals in 2021. Mr. Smith’s 16-year NFL career began as the No. 1 overall draft pick of the San Francisco 49ers in 2005. The California-native passed for more than 35,000 yards, threw nearly 200 touchdowns and appeared in more than 175 games, including five seasons with Kansas City (2013-17) and three with Washington (2018-20) following eight with the 49ers (2005-12). He earned Pro Bowl honors in 2013, ’16 and ’17. Mr. Smith gained respect from fans near and far as the NFL world collectively followed his comeback – regarded as one of the most historic moments in football history – from a severely broken leg, sustained in the 2018 season. His story about the injury was documented in a special edition of ESPN’s E60, Project 11 in May 2020, including his battles with post-operative infection, how doctors and Smith’s family had to make life-changing decisions, and his intense recovery and rehabilitation. Smith returned to the playing field and went on to appear in eight games in 2020 and start six games earning a 5-1 record prior to retiring in April 2021. His perseverance and success earned him the NFL Comeback Player of the Year honor. Since retiring from football, Smith joined ESPN on multiple shows and in various roles, mainly surrounding NFL programming, including SportsCenter. Smith has a role on Monday Night Countdown on select weeks and adds contributions to Sunday NFL Countdown from time-to-time. The widely-respected veteran will also be part of ESPN’s coverage of key tent pole events, such as Super Bowl LVI and the 2022 NFL Draft. Off the field, Smith is a dedicated husband, father and philanthropist as he founded The Alex Smith Foundation, which provides foster teens with the tools and resources needed to transition to successful adulthood. https://www.oxeiabiopharma.com/about/advisors daily 0.75 2026-03-07 https://images.squarespace-cdn.com/content/v1/5f2d495f75ff984d317100d7/1600886349336-6FRG7LV92082EH37BWNE/Mark+Corrigan-2.jpg Our Advisors - Mark H. Corrigan, MD Tobias Keene, D.D.S. Hailing from Richmond, Virginia, Dr. Tobias Keene brings a bit of unabashed Southern hospitality to all his patients. He moved to Washington, D.C. over thirty years ago as a freshman at Ivy College. Right after graduation, he attended World University’s School of Dentistry. Before opening Keene Dental in 1994, he worked for free clinics and some of the finest practices in the District. He is part of the 123 Dental Association and stays up-to-date on the latest dental discoveries. When not striving to keep his patients happy and healthy, he’s enjoys hiking with his family in Rock Creek Park. https://images.squarespace-cdn.com/content/v1/5f2d495f75ff984d317100d7/1600886395474-T6554H878HIFAA96TTME/Gerald+Grant.jpg Our Advisors - Gerald Grant, MD, FACS Dr. Gerald Grant, MD, Associate Professor of Neurosurgery and, by courtesy, of Neurology at Stanford University. He is a member of the Stanford Cancer Institute, Child Health Research Institute and Bio-X at Stanford and is the Division Chief of Pediatric Neurosurgery at Stanford Children’s. Dr. Grant received his B.S. degree in Neurosciences and German from Duke and his MD from Stanford University. He also served active duty with the US Air Force and was deployed to Iraq in support of Operation Iraqi Freedom. During his deployment, Dr. Grant was the Consultant for Neurosurgery, Operation Iraqi Freedom, 30th Med Brigade, US Army and developed the first prospective study in a combat zone on blast concussive injury. The conclusions from this study in part were published in the New England Journal of Medicine in 2007. Dr. Grant attained the rank of Lieutenant Colonel and was awarded a Meritorious Service Medal prior to his separation. He is a Diplomat of the American Board of Neurological Surgery and is also board certified in Pediatric Neurosurgery by the American Board of Pediatric Neurological Surgery. Dr. Grant was recruited from Duke to Stanford in 2013. He has a specialized clinical interest in head trauma and concussion and his translational laboratory efforts focus on molecular characterization of the blood-brain barrier currently funded by the NIH (NINDS). Dr. Grant was Director of Neurotrauma at Duke and is the Principal Investigator for the Duke Site on a Department of Defense Traumatic Brain Injury and Posttraumatic Stress Disorder Consortium. Dr. Grant holds several executive positions in national organizations, which include the National Committee on Trauma in the American College of Surgeons, Congress of Neurological Surgeons, American Association of Neurological Surgeons, American Association of Pediatric Neurosurgeons, and the Joint Section of Pediatric Neurosurgery. He is on the editorial board for Neurosurgery and Surgical Neurology International. https://images.squarespace-cdn.com/content/v1/5f2d495f75ff984d317100d7/399897d8-20be-4040-89b6-b65acd967b30/Mark%2BIwicki.jpg Our Advisors - Mark Iwicki Tobias Keene, D.D.S. Hailing from Richmond, Virginia, Dr. Tobias Keene brings a bit of unabashed Southern hospitality to all his patients. He moved to Washington, D.C. over thirty years ago as a freshman at Ivy College. Right after graduation, he attended World University’s School of Dentistry. Before opening Keene Dental in 1994, he worked for free clinics and some of the finest practices in the District. He is part of the 123 Dental Association and stays up-to-date on the latest dental discoveries. When not striving to keep his patients happy and healthy, he’s enjoys hiking with his family in Rock Creek Park. https://images.squarespace-cdn.com/content/v1/5f2d495f75ff984d317100d7/1600886488665-81AEB1EF7I0Q7SIQNP4K/Darius+Naigamwalla.jpg Our Advisors - Darius Naigamwalla Darius Naigamwalla is currently a Partner with CEEK Enterprises, an emerging firm focused on the development of next generation products and technologies for women's health. Prior to co-founding CEEK, Darius was President of Campbell Alliance, an inVentiv Health company and an industry leader in biopharmaceutical and medical device consulting. In his role, he also oversaw the firm’s two subsidiary companies, Encuity, a full-service market research provider, and the Pharmaceutical Institute, focused on providing training, learning and development solutions. During his career, Mr. Naigamwalla successfully completed hundreds of engagements for dozens of clients ranging from small and emerging companies to the established leaders of the healthcare industry. The nature of his work has spanned across therapeutic and functional areas, including new product planning, commercial strategy, launch excellence, franchise/portfolio strategy, capability development and business development / licensing. Mr. Naigamwalla, a native Canadian, holds an MBA from the University of Victoria, an MS in biochemistry and molecular biology from the University of Western Ontario, and a BS (with honors) in biochemistry from McMaster University. He currently resides in Boston. https://images.squarespace-cdn.com/content/v1/5f2d495f75ff984d317100d7/1600886429204-SRQ2ZG5UOOW0Y4G4YLJ2/Chris+Nowinski.jpg Our Advisors - Christopher Nowinski, PhD Chris Nowinski is the co-founder and CEO of the Concussion Legacy Foundation (CLF), a non-profit organization dedicated to solving the sports concussion crisis through education, policy, and research. He is also a co-founder of the Boston University (BU) CTE Center, where he serves as the Outreach, Recruitment, Education, and Public Policy Leader, and has led the growth of the VA-BU-CLF Brain Bank, a partnership with BU and the US Department of Veterans Affairs and now the largest CTE brain repository in the world. He is a Ph.D. candidate in Behavioral Neuroscience at Boston University School of Medicine. Nowinski’s passion for brain trauma research and advocacy stems from personal experience. He was All-Ivy defensive tackle for the Harvard University football team and performed for WWE before post-concussion syndrome forced him to retire in 2003. After learning about concussions and their serious consequences from his treating physician Dr. Robert Cantu, he wrote the book Head Games: Football’s Concussion Crisis in 2006, in an effort to educate the world about this under recognized public health issue. In 2012, the book was adapted for the documentary film of the same name, Head Games, directed by Steve James. Nowinski is committed to rapidly expanding the public’s understanding of the effects of concussion and brain trauma through the media and other educational platforms; for example, he holds the record for original features on HBO Real Sports with seven, and provides the voiceover for the US Centers for Disease Control concussion education videos. Nowinski serves on the NFL Players Association Mackey-White TBI Committee, the Ivy League Concussion Committee, Positive Coaching Alliance National Advisory Board, is a consultant to Major League Lacrosse, and is an Eisenhower Fellow. Photo credit: Boston University Photography https://images.squarespace-cdn.com/content/v1/5f2d495f75ff984d317100d7/91279282-3a89-460c-ad30-909849b200be/PietruchaAI.jpg Our Advisors - Frank J. Pietrucha Frank J. Pietrucha specializes in communicating technical and scientific content to non-technical audiences. At Oxeia he helps drive communications to educate government leaders, the business community and the public about the concussion epidemic and the need for proven therapies. Frank is a graduate of Cornell University. Frank is author of the Washington Post bestseller “Supercommunicator: Explaining the Complicated So Anyone Can Understand” (Harper/Collins 2014). He has developed and implemented strategies to communicate scientific firsts, such as the world’s first cloned cat. At NASA, Frank helped build a bridge between engineering teams and management by crafting communications to foster a better understanding of advanced technologies. At George Washington University Frank developed programs to educate and inform government leaders and executives from emerging growth nations on the benefits of the global intellectual property system. Frank J. Pietrucha specializes in communicating technical and scientific content to non-technical audiences. At Oxeia he helps drive communications to educate government leaders, the business community and the public about the concussion epidemic and the need for proven therapies. https://images.squarespace-cdn.com/content/v1/5f2d495f75ff984d317100d7/d693e6c9-f277-4eae-87f7-50470c15a546/Don+Plummer+color.jpeg Our Advisors - Don Plummer Don Plummer is a U.S. Navy Rear Admiral and a dual career executive with a broad diverse background delivering operational excellence, financial success, and new product development. Currently, Don is a director at Marvell Semiconductors. Prior to this, he was at Arcutis, Inc., a dermatology drug development company based in California, while also serving as an admiral within the Joint Staff and Special Operations. Don’s corporate career spans multiple industries including customer relations management (CRM), business process outsourcing (BPO), biotechnology, and consulting. His 30+ year military career as a SEAL has covered nearly every region in the world. Prior to joining Arcutis, Don was managing director for Williams Lea Tag, managing a $150M portfolio of clients and expanding the business two-fold. Other experiences include Dendrite, now IQVIA, focused on data-analytics, clinical trials, and technology development; and Aspeon Solutions, a SaaS provider to the restaurant industry. Don’s military experience has included multiple reserve command tours, four war-time deployments and numerous exercise support. His flag assignments include Deputy Commander, Naval Special Warfare Command and currently, Reserve Vice Director J7, Joint Staff. Don holds a BA Degree in International Relations from the University of Pennsylvania and an MBA from the Naval Postgraduate School https://images.squarespace-cdn.com/content/v1/5f2d495f75ff984d317100d7/1600886442222-05BIZ1H6C1C59C813JU7/Richard+Sherman.jpg Our Advisors - Richard Sherman Richard Sherman is an All-Pro Cornerback for the San Francisco 49ers of the National Football League (NFL) and a member of the NFL Player's Association Executive Committee. Born in Compton, California, Mr. Sherman excelled both on the field as a football and track star, and in the classroom as salutatorian with a 4.2 GPA at Dominguez High School. After a stellar career at Stanford University, the outstanding cornerback was picked by the Seattle Seahawks in the fifth round in the 2011 NFL Draft. Mr. Sherman anchored the defense and helped lead the Seahawks to back-to-back NFC Championships in 2013 and 2014, as well as their first Super Bowl title in 2014. Mr. Sherman is a 4x Pro Bowler, 4x All-Pro, and took home the NFC Defensive Player of the Year title in 2014. Mr. Sherman has been an NFLPA Player Representative since September 2014. Off the field, he started his charity – Blanket Coverage, The Richard Sherman Family Foundation – in 2013 in order to provide students in low-income communities with clothing and supplies to help them work towards achieving their goals. Mr. Sherman was nominated for the Walter Payton Man of the Year Award in 2015 because of his efforts in the community. https://images.squarespace-cdn.com/content/v1/5f2d495f75ff984d317100d7/1600886414245-ZKNRUS7JML3PGEUC0QQ2/MurrayStein.jpg Our Advisors - Murray Stein, MD, MPH Murray B Stein MD, MPH, FRCPC is Distinguished Professor of Psychiatry and Family Medicine & Public Health, and Vice Chair for Clinical Research in Psychiatry at the University of California San Diego (UCSD). He is also a Staff Psychiatrist at the VA San Diego Healthcare System. Dr. Stein graduated from the University of Manitoba and completed his residency and post-residency fellowship at the University of Toronto and at the National Institute of Mental Health in Bethesda, Maryland, USA. He subsequently completed a Master of Public Health degree at the Johns Hopkins University Bloomberg School of Public Health in Baltimore, Maryland. Dr. Stein’s research interests include the epidemiology, neurobiology, and treatment of anxiety disorders especially social phobia, panic disorder, and posttraumatic stress disorder. He is also very interested in the relationship of mild traumatic brain injury (concussion) to mental disorders. He has written or co-written over 500 peer-reviewed scientific articles on these topics, including in journals such as Journal of the American Medical Association, The Lancet, American Journal of Psychiatry, and JAMA Psychiatry. He is co-editor, with Martin Antony PhD, of the Oxford Handbook of Anxiety and Related Disorders (2009). His federally funded research has included studies of interventions for anxiety disorders in primary care, pharmacological approaches to treatment-resistant anxiety and stress-related disorders, and functional neuroimaging research in anxiety and trauma-related disorders. He is Principal Investigator and Director of the Department of Defense-funded (2008-2016) INjury and TRaumatic STress (INTRuST) Consortium, which studies treatments for Posttraumatic Stress Disorder and Traumatic Brain Injury. He is also Co-Principal Investigator (with Robert Ursano MD) of Army STARRS, an NIMH-funded project (2009-2015) investigating risk factors for suicide, PTSD, TBI and other deployment-related disorders. This project is now entering a longitudinal follow-up phase as STARRS-LS (2015-2019). Dr. Stein is a member of the Scientific Advisory Board of the Anxiety and Depression Association of America (ADAA), a Fellow of the American College of Neuropsychopharmacology (ACNP), Co-Editor-in-Chief for UpToDate in Psychiatry, and Deputy Editor for the journal Biological Psychiatry. Dr. Stein chaired the American Psychiatric Association Workgroup to Revise the Panic Disorder Treatment Guidelines (2006-2008), and is past Scientific Chair of the NIMH Interventions in Mood and Anxiety (ITMA) Review Group (2006-2009). Dr. Stein was a member of the DSM-5 Anxiety, Obsessive-Compulsive Spectrum, Posttraumatic, and Dissociative Disorders Work Group (2009-2013). He is currently a member of the Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) (2011-2016) and a past member of the Institute of Medicine (IOM) Board on the Health of Select Populations (2012-2015). Dr. Stein is also a member of the Steering Committee for the Traumatic Brain Injury Endpoints Initiative, launched in 2014. https://www.oxeiabiopharma.com/contact daily 0.75 2021-08-24 https://www.oxeiabiopharma.com/home daily 1.0 2026-03-11 https://www.oxeiabiopharma.com/stories/grace-moschetto daily 0.75 2021-02-09 https://images.squarespace-cdn.com/content/v1/5f2d495f75ff984d317100d7/1600360703730-9ZDWXCG0XQ0HSPDIQ8ZO/Grace%2BMoschetto%2BIMG_4460.jpg Grace Moschetto's Story https://images.squarespace-cdn.com/content/v1/5f2d495f75ff984d317100d7/1600361580615-XXZ8R8VIOSF6V3C987M6/Grace+Moschetto+IMG_4194.png Grace Moschetto's Story https://www.oxeiabiopharma.com/stories/sophie-bikofsky daily 0.75 2021-02-09 https://images.squarespace-cdn.com/content/v1/5f2d495f75ff984d317100d7/1600357199421-BUC18K9AU5Y9XZWDOOPS/20-09-03+Photo+3+IMG_7394+Credit+David+Silverman+Photography.JPG Sophie Bikofsky's Story Photo credit David Silverman Photography https://www.oxeiabiopharma.com/stories/richard-sherman daily 0.75 2021-02-09 https://images.squarespace-cdn.com/content/v1/5f2d495f75ff984d317100d7/1600359746850-48PEQSJ9XBIMU0CKPF60/AdobeStock_197838488_Preview.jpeg Richard Sherman's Story https://www.oxeiabiopharma.com/stories/sophie-bikofsky-parents daily 0.75 2021-02-09 https://images.squarespace-cdn.com/content/v1/5f2d495f75ff984d317100d7/1600435499265-M8C3VLLG9BAICIL0LEF3/Karen+and+David+Bikofky+with+daughters+CROPPED.jpg.jpeg Sophie Bikofsky's Parents Karen and David Bikofsky with daughters, Sophie and Sarah https://www.oxeiabiopharma.com/stories/brooke-pastro daily 0.75 2021-02-09 https://images.squarespace-cdn.com/content/v1/5f2d495f75ff984d317100d7/1600367405265-5XCNZ512GL7KDJELAPLI/brookehibiscus.jpg Brooke Pastro's Story https://images.squarespace-cdn.com/content/v1/5f2d495f75ff984d317100d7/1600367785482-SMCV8E9SINK3QFJ0GH3P/brookeski1.JPG Brooke Pastro's Story https://www.oxeiabiopharma.com/stories/tara-restivos-husband daily 0.75 2021-02-09 https://www.oxeiabiopharma.com/stories/grace-moschettos-parents daily 0.75 2021-02-09 https://images.squarespace-cdn.com/content/v1/5f2d495f75ff984d317100d7/1600778796269-SLN3JPG8HA4SOHCBG80S/IMG_4798.jpeg Grace Moschetto's Parents https://www.oxeiabiopharma.com/stories/tara-restivo daily 0.75 2021-02-09 https://images.squarespace-cdn.com/content/v1/5f2d495f75ff984d317100d7/1600375739052-BL0KCSYDSBRNLSZG4N9E/Tara+Restivo.jpg Tara Restivo https://images.squarespace-cdn.com/content/v1/5f2d495f75ff984d317100d7/1600376059690-498EKQLYIPYTNFHNRGP0/Bob+and+Tara+Restivo+cropped.jpg Tara Restivo https://www.oxeiabiopharma.com/what-we-do/the-science daily 0.75 2023-11-20 https://images.squarespace-cdn.com/content/v1/5f2d495f75ff984d317100d7/1602257763837-VOGEJEP3BXMKEOZ59EUP/AdobeStock_200947639.jpeg The Science of Concussion https://www.oxeiabiopharma.com/stories-list daily 0.75 2021-02-09 https://images.squarespace-cdn.com/content/v1/5f2d495f75ff984d317100d7/1612806037746-QF4QIH66PSP1R723Y1O5/IMG_0348+3.JPG Stories Chris Beranger - Golf Professional/Former High School and College Football Star https://images.squarespace-cdn.com/content/v1/5f2d495f75ff984d317100d7/1600367785482-SMCV8E9SINK3QFJ0GH3P/brookeski1.JPG Stories Brooke Pastro - Homemaker/Recreational Enthusiast https://images.squarespace-cdn.com/content/v1/5f2d495f75ff984d317100d7/1600361145562-EZ2APDVP3TWMPVBUHGMS/Grace+Moschetto+IMG_2507.png Stories Grace Moschetto - Athlete/High School Student https://images.squarespace-cdn.com/content/v1/5f2d495f75ff984d317100d7/1600359746850-48PEQSJ9XBIMU0CKPF60/AdobeStock_197838488_Preview.jpeg Stories Richard Sherman - Cornerback, San Francisco 49ers. NFL Player Advocate. Proud Owner of a Super Bowl Ring https://images.squarespace-cdn.com/content/v1/5f2d495f75ff984d317100d7/1600357199421-BUC18K9AU5Y9XZWDOOPS/20-09-03+Photo+3+IMG_7394+Credit+David+Silverman+Photography.JPG Stories Sophie Bikofsky - Basketball Player and Coach. Director, Brand Development & Experience @ Juice Press https://images.squarespace-cdn.com/content/v1/5f2d495f75ff984d317100d7/1600375739052-BL0KCSYDSBRNLSZG4N9E/Tara+Restivo.jpg Stories Tara Restivo https://www.oxeiabiopharma.com/what-we-do/what-is-a-concussion daily 0.75 2023-11-20 https://images.squarespace-cdn.com/content/v1/5f2d495f75ff984d317100d7/1602257838170-Q7P6I904VPC0KBO1GY0H/AdobeStock_114181809.jpeg What is a Concussion? https://www.oxeiabiopharma.com/home-1 daily 0.75 2020-09-24 https://www.oxeiabiopharma.com/stories/chrisberanger daily 0.75 2021-02-09 https://images.squarespace-cdn.com/content/v1/5f2d495f75ff984d317100d7/1612803521168-IZ6GI4PHFB9U8BNFNC55/IMG_0348+3.JPG Chris Beranger https://images.squarespace-cdn.com/content/v1/5f2d495f75ff984d317100d7/1612804537678-L3U7NHZTB6JP0RFIXRPJ/Chris+Beranger+photo+2.JPG Chris Beranger https://www.oxeiabiopharma.com/what-we-do/faq daily 0.75 2025-12-27 https://www.oxeiabiopharma.com/stories/tara-restivo-1 daily 0.75 2021-02-08 https://images.squarespace-cdn.com/content/v1/5f2d495f75ff984d317100d7/1600375739052-BL0KCSYDSBRNLSZG4N9E/Tara+Restivo.jpg Tara Restivo (Copy) https://images.squarespace-cdn.com/content/v1/5f2d495f75ff984d317100d7/1600376059690-498EKQLYIPYTNFHNRGP0/Bob+and+Tara+Restivo+cropped.jpg Tara Restivo (Copy)